Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2010 Feb;14(1):81-6.
doi: 10.1188/10.CJON.81-86.

Managing neutropenia in older patients with cancer receiving chemotherapy in a community setting

Affiliations
Clinical Trial

Managing neutropenia in older patients with cancer receiving chemotherapy in a community setting

Irene Q Flores et al. Clin J Oncol Nurs. 2010 Feb.

Abstract

Older patients with cancer who may be more susceptible than younger patients to the myelosuppressive effects of chemotherapy undergo dose delays and reductions that can compromise treatment outcomes. Incidence of neutropenic complications and suboptimal chemotherapy delivery can be reduced with prophylactic colony-stimulating factors; however, their use in older patients with cancer has not been well studied. A randomized, multicenter, community-based trial was designed to compare prophylactic pegfilgrastim use (all cycles of chemotherapy) versus its more common reactive use (at clinicians' discretion) in patients aged 65 years or older with various cancers. Pegfilgrastim use in all cycles reduced the incidence of febrile neutropenia by about 60% and hospitalizations caused by neutropenia and febrile neutropenia by about 50% versus reactive pegfilgrastim use in later cycles. The study showed that older patients with cancer can be treated safely with optimal doses of chemotherapy with appropriate supportive care. Nurses, key collaborators in providing supportive care, can take an active role in identifying older patients who may benefit from pegfilgrastim in all cycles of chemotherapy.

PubMed Disclaimer

References

    1. Aapro MS, Cameron DA, Pettengell R, Bohlius J, Crawford J, Ellis M, Zielinski C. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. European Journal of Cancer. 2006;42:2433–2453. doi: 10.1016/j.ejca.2006.05.002. - DOI - PubMed
    1. Aapro MS, Kohne CH, Cohen HJ, Extermann M. Never too old? Oncologist. 2005;10:198–204. doi: 10.1634/theoncologist.10-3-198. - DOI - PubMed
    1. Balducci L, Al-Halawani H, Charu V, Tam J, Shahin S, Dreiling L, Ershler WB. Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. Oncologist. 2007;12:1416–1424. doi: 10.1634/theoncologist.12-12-1416. - DOI - PubMed
    1. Balducci L, Extermann M. Management of cancer in the older person: A practical approach. Oncologist. 2000;5:224–237. - PubMed
    1. Bennett CL, Somerfield MR, Pfister DG, Tomori C, Yakren S, Bach PB, American Society of Clinical Oncology Perspectives on the value of American Society of Clinical Oncology clinical guidelines as reported by oncologists and health maintenance organizations. Journal of Clinical Oncology. 2003;21:937–941. doi: 10.1200/JCO.2003.07.165. - DOI - PubMed

Publication types

MeSH terms